Vitamins (n=386) | Placebo (n=366) | Comparison (99% CI) | p Value | |
Chest symptoms in first 12 months | ||||
Asthma | 6.0% | 6.3% | 0.94 (0.42 to 2.11) | 0.855 |
Eczema | 25.4% | 23.5% | 1.10 (0.70 to 1.74) | 0.586 |
Cough | ||||
At all | 70.5% | 74.9% | 0.81 (0.50 to 1.29) | 0.245 |
More than once/week | 10.6% | 11.5% | 0.90 (0.47 to 1.74) | 0.679 |
Wheeze | ||||
At all | 23.3% | 28.1% | 0.78 (0.50 to 1.21) | 0.144 |
More than once/week | 3.9% | 4.6% | 0.81 (0.32 to 2.06) | 0.568 |
Chest symptoms in second 12 months | ||||
At all | 86.8% | 85.8% | 1.08 (0.59 to 1.97) | 0.752 |
More than once/week | 13.2% | 10.1% | 1.33 (0.71 to 2.51) | 0.246 |
Wheeze | ||||
At all | 25.9% | 26.5% | 0.97 (0.62 to 1.52) | 0.852 |
More than once/week | 2.6% | 3.0% | 0.83 (0.26 to 2.59) | 0.669 |
Medications for chest problems | ||||
Medicines (ever) | 38.6% | 45.4% | 0.75 (0.50 to 1.13) | 0.068 |
Medicines (in last 12 months) | 29.5% | 36.6% | 0.72 (0.47 to 1.09) | 0.041 |
Bronchodilators | 13.7% | 13.1% | 1.06 (0.60 to 1.88) | 0.789 |
Antibiotics | 26.4% | 32.0% | 0.75 (0.49 to 1.16) | 0.092 |
Preventors | 5.4% | 7.4% | 0.72 (0.33 to 1.59) | 0.288 |
Palivizumab | 1.6% | 0.8% | 1.80 (0.29 to 11.2) | 0.407 |
Hospital admissions | ||||
For breathing difficulties | 8.5% | 11.7% | 0.70 (0.37 to 1.33) | 0.153 |
n | 33 | 43 | ||
Number of days (if any) | 6.2 (12.2) | 4.3 (6.4) | 1.9 (−1.9 to 13.9) | 0.416 |
Other admissions | 14.2% | 15.6% | 0.91 (0.52 to 1.6) | 0.665 |
n | 55 | 57 | ||
Number of days (if any) | 10.2 (26.2) | 5.0 (10.3) | 5.3 (−1.6 to 23.9) | 0.158 |
Admissions to ICU | 3.6% | 1.9% | 2.0 (0.52 to 7.4) | 0.195 |
n | 14 | 7 | ||
Number of days (if any) | 24.1 (24.0) | 13.1 (24.7) | 10.9 (−51.4 to 32.4) | 0.379 |
Results shown are mean (SD) or percentages as appropriate.
Comparisons are differences in means or ORs with 99% CIs, adjusted for effect of multiple pregnancy and for clustering by mother.
For number of days in hospital, CIs are by bias-corrected bootstrap with 10 000 replications.